赛乐特治疗抑郁症的临床疗效观察

目的评价赛乐特对治疗抑郁症的临床疗效和不良反应。方法入选96例患者,随机分为治疗组54例和对照组42例。对照组给予多虑平片50mg,3次／d,疗程8周;治疗组给予赛乐特片20mg,1次／d,疗程8周。8周后观察临床疗效。结果治疗组疗效明显优于对照组,且不良反应发生率低。结论赛乐特具有较好的抗抑郁作用,且不良作用少、安全。     

百忧解治疗早泄疗效观察

目的观察百忧解治疗早泄近期疗效及安全性。方法将36例早泄病人每日早晨服百忧解20mg连用4w，随访4w。结果总有效率88％，平均射精潜伏期延长至8min。随访4w复发率25％。副作用小。结论百忧解治疗早泄是一种安全有效的方法，近期疗效好，值得推广。停药后复发，药物维持治疗并用行为疗法可能是巩固疗效的最好办法。     

恩纳乳膏治疗早泄的临床疗效观察

<正> 早泄是男性性功能障碍最常见的症状之一,在阴茎局部涂抹麻醉剂,能降低阴茎局部对性刺激的敏感性,可延长射精潜伏期,起到治疗早泄的目的。恩纳乳膏是一种油/水乳化胶,是由利多卡因和丙胺卡因以1:1比例混于油溶剂中,可     

中医药外治法治疗早泄60例临床观察

目的：观察中医药外治方法治疗早泄的效果。方法：将120例早泄患者随机分为对照组和观察组,对照组单纯应用中药内服治疗,治疗组在对照组基础上综合运用针刺、埋线、艾灸、推拿按摩、中药药液外涂等中医外治疗法。比较两组治疗效果。结果：治疗1个月后,观察组有效率为96%,对照组为76%,观察组疗效优于对照组。结论：中医外治法有改善早泄症状的作用,可以推广使用。     

盐酸舍曲林治疗早泄疗效观察

目的 观察盐酸舍曲林(左洛复)治疗早泄的临床疗效.方法 对60例早泄患者予以左洛复治疗,每次50 mg,口服、每天1次,连续服用1个月后停药.疗效评价采用中国早泄患者性功能评价表 (CIPE),比较治疗前与治疗1、2、4周和停药后8周时的平均射精潜伏期、患者及其配偶的性生活满意度.结果 治疗后平均射精潜伏期延长,患者和配偶性生活满意度均有明显改善,疗效与患者年龄和患病时间的长短无关.结论 盐酸舍曲林治疗早泄疗效确切.     

阴茎背神经切断术治疗原发性早泄疗效观察

随着人们生活水平的不断提高,人们对性生活的要求也越来越高,而射精障碍则严重地影响着正常的夫妻感情.早泄(premature ejaculation,PE)作为射精障碍中最常见的疾病,已逐渐成为男性患者和临床男科不容回避和迫切需要解决的一个重要课题.近年来的研究发现,阴茎的感觉过敏或阴茎感觉神经兴奋性增高等器质性因素是引起早泄的重要病因,而阴茎背神经分支切断术是通过切断部分阴茎背神经来降低阴茎的敏感性,延长阴道内射精潜伏期,从而达到治疗PE的目的.2009年11月-2012月5月,我科采用阴茎背神经切断术治疗原发性PE 92例,疗效满意,现报告如下.     

佐洛复治疗慢性前列腺炎合并早泄63例疗效观察

慢性前列腺炎（CP）发病率为5％～8％，是男性泌尿外科最常见的疾病之一，约占泌尿外科门诊患者的1／5.早泄（PE）是射精障碍中最常见的疾病，发病率占成人男子35％～50％，占射精障碍90％。本站自2003年11月～2006年6月对63例CP合并PE患者采用抗抑郁药佐洛复片（盐酸舍曲林）延迟射精作用，取得比较满意的效果。     

早泄患者慢性前列腺炎患病情况的临床研究

目的　了解早泄患者慢性前列腺炎的患病情况。方法　 6 8例早泄患者 ,常规检查前列腺液、前列腺按摩前后尿液 ,并做细菌学研究。选 30例健康人为正常对照。结果　早泄患者中慢性细菌性前列腺炎、慢性非细菌性前列腺炎的检出率分别为 4 7.1%和 2 3.5 % ,与对照组相比差异具有显著性 (P <0 .0 5 )。结论　慢性前列腺炎可能在早泄的发病机制中起着重要作用。因此 ,在对早泄患者进行药物及心理治疗之前仔细检查前列腺至关重要。     

The psychophysiological nature of premature ejaculation

The hypothesis that premature ejaculators (PEs) are less able than nonpremature ejaculators (NPEs) to evaluate accurately their level of physiologically determined sexual arousal was tested. Twenty-six men (13 PEs and 13 NPEs) viewed a variety of videotaped vignettes, some of which were excerpts from sexually explicit films. Concurrent subjective (selfreport) and objective (plethysmograph) ratings of sexual arousal were taken. Data revealed that both the PEs and NPEs were equally accurate in assessing their level of physiological sexual arousal. These results and those from a sexual history questionnaire were used to evaluate several hypotheses regarding the nature and etiology of premature ejaculation.This research was supported in part by an NIH Biomedical Research Support Grant RR-07092 to the first author.     

不同体重指数男性不育症患者早泄评估

目的调查不同体重指数男性不育症患者早泄（PE）分布情况。方法随机抽取男性不育症患者292例,按照不同体重指数分组,正常组84例,超重组117例,肥胖组91例。使用中国早泄患者性功能评价表（CIPE）调查患者早泄情况。结果男性不育症患者总的PE患病率为37．3％。超重组CIPE评分（37．8±6．8）低于正常组（39．1±7．1）,肥胖组评分（34．8±6．4）低于正常组和超重组;肥胖组PE患病率（50．5％）高于正常组（25．0％）,肥胖组PE患病率高于超重组（35．9％）,差异均有统计学意义。结论体重指数对于男性不育症患者的早泄有明显影响。减轻体重对男性不育症患者的早泄治疗较重要。     

帕罗西汀联合黛力新治疗惊恐障碍的疗效观察

目的 评价盐酸帕罗西汀联合黛力新治疗惊恐障碍的临床疗效及其不良反应。方法 将符合CCMD-3诊断标准的32例惊恐障碍患者每日给予盐酸帕罗西汀10mg和黛力新1片，连续治疗1个月，采用汉密尔顿焦虑量表（HAMA）和不良反应量表（TESS）评定疗效和药物不良反应。结果 所有32例患者均完成了1个月的临床观察。治疗前后HAMA减分比较差异有非常显著（P〈0．01），临床疗效评定显效率为和有效率均为100％。盐酸帕罗西汀联合黛力新治疗的不良反应轻微。结论 盐酸帕罗西汀联合黛力新治疗惊恐障碍安全有效，依从性好。     

The role of anxiety in premature ejaculation: A psychophysiological model

Despite the prevalence of premature ejaculation and the success in its treatment, researchers have yet to offer a compelling, empirically based theory regarding its nature or etiology. This study explored a model that argues that anxiety may not be necessary for the existence of this dysfunction. Fifteen premature ejaculators (PEs) and 17 nonpremature ejaculators (NPEs) engaged in self-stimulation to orgasm both in the laboratory and at home. The following specific hypotheses were tested: Compared to NPEs, PEs would demonstrate (i) shorter orgasmic latencies, both in the lab and at home, and (ii) equally accurate estimates of these latencies. Results offered strong support for both hypotheses. These findings, and those derived from a questionnaire completed by subjects, were seen as consistent with a psychophysiologic model of premature ejaculation. According to this model, the role of anxiety is seen as variable, interacting with the somatic vulnerability of the individual to determine orgasmic latency.This research was supported by an NIH Biomedical Research Support Grant #2S07RR07092 to the first author.     

Indirect behavioral treatment of erectile failure and premature ejaculation in a man without a partner

Premature ejaculation and erectile failure in a 54-year-old man were treated by a combination of exposure in vivo and social skills training. The intervention was not aimed directly at the dysfunctional sexual response but at features of the patient's interpersonal behavior hypothesized to be instrumental in maintaining it. Change was assessed on the basis of the patient's records of weekly rate of successful intercourse, performance of target behaviors, and associated anxiety within a single-case multiple baseline design. Change occurred only with the introduction of treatment and not before it, ruling out the effect of mere therapeutic contact or passage of time. The intervention resulted in an increased rate of performance of adaptive social targets in real life, a decrease in associated anxiety, and eventually a correlated moderate increase in the rate of successful intercourse. The outcome maintained for 1-year follow-up. Systematic data collection was discontinued after 6 months.     

Pituitary gonadal system function in patients with erectile impotence and premature ejaculation

The pituitary testicular system was studied in men with psychogenic impotence. Eight patients with primary erectile impotence age 22–36 years, eight men with secondary erectile impotence age 29–55 years, and 16 men with premature ejaculation age 23–43 years were studied. The last group was further divided into two subgroups: E₁ (n = 7) patients without and E₂ (n = 9) patients with anxiety and avoidance behavior toward coital acitivity. Sixteen normal adult men age 21–44 served as a control group. Diagnosis was made after psychiatric and physical examinations. Patients complaining primarily of loss of libido were not considered in the study. Ten consecutive blood samples were obtained over a period of 3 hr from each patient. Luteinizing hormone (LH), total testosterone, and free (not protein-bound) testosterone were measured. Statistical analysis revealed no significant differences between patients and normal controls.     

Treatments of premature ejaculation and psychogenic impotence: A critical review of the literature

Research on the treatments of premature ejaculation and psychogenic impotence is reviewed. Problems with the existing definitions of these disorders are discussed. The studies are reviewed under seven major headings: depth therapies, behavior therapies, hypnosis, drug therapy, mechanotherapy, reeducative and supportive therapies, and extensive retraining programs. Most of the studies were case reports. Considerable methodological weaknesses were found, most notably the failure to specify subject and treatment variables, the confounding of treatment methods, inadequate or nonexistent control groups, limited, if any, follow-up assessments of treatment effects, and a failure to obtain partner validation of subjects' progress. The studies which used systematic desensitization and the studies which assessed the extensive retraining programs reported the most consistently positive results, although better-controlled replications are needed. Among other issues, it was suggested that future investigators examine the impact of treatment on homogeneous samples and conduct controlled comparisons of different treatment methods.